Haemophilus

Global Central Nervous System Partnering 2023: Information on Every Deal Since 2016 - ResearchAndMarkets.com

Retrieved on: 
Mercoledì, Aprile 12, 2023
Health, Biotechnology, Chapter Four, Influenza B virus, Central nervous system, Disease, Traumatic brain injury, Sympathetic nervous system, TB, Dizziness, A-Z, Stroke, Research, Directory, Weakness, Orientation, Headache, CNS, Chapter Three, Multiple sclerosis, Vertigo, Chapter One, Restless, Migraine, Chapter Two, Chapter Five, Chapter Six, Collection, Guillain–Barré syndrome, Peripheral neuropathy, Creutzfeldt–Jakob disease, Parkinson's disease, Amyotrophy, Spinal cord, ALS, Cerebral palsy, Hyperlink, Bacteria, Restless legs syndrome, Mycobacterium tuberculosis, Pharmaceutical industry, Music, Bank, Drug, Cryptocurrency, Medical device, Nausea, Haemophilus, Epilepsy, Pain, Neuralgia, Fibromyalgia, Paralysis, Stuttering, Meningitis

Global Central Nervous System Partnering 2016 to 2010 provides the full collection of central nervous system disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.

Key Points: 
  • Global Central Nervous System Partnering 2016 to 2010 provides the full collection of central nervous system disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.
  • The report takes readers through the comprehensive central nervous system disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering central nervous system deals.
  • Chapter 6 provides a comprehensive directory of all central nervous system partnering deals by specific central nervous system target announced since 2016.
  • Global Central Nervous System Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to central nervous system trends and structure of deals entered into by leading companies worldwide.

China Vaccine Market Report 2023 to 2027 - Featuring Walvax Biotechnology, Beijing Tiantan Biological Products, Sinovac Biotech and Shenzhen Kangtai Biological Products Among Others - ResearchAndMarkets.com

Retrieved on: 
Martedì, Gennaio 31, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Other Health, Administration, Vaccination, Meningitis, Attenuated vaccine, Meningococcal disease, Rabies, MPSV4, Conjugate vaccine, Safety, Sinovac Biotech, PCV13, Expanded Program on Immunization, Infant, EPI, Sinopharm Group, Birth rate, Category, Parent, Pneumococcal polysaccharide vaccine, Forecasting, Policy, DTP, COVID-19, Category 2, R, Ageing, Pharmaceutical industry, Vaccine, Haemophilus, Immunization

As a result, China has drawn significant attention to the vaccine industry to play a representative role.

Key Points: 
  • As a result, China has drawn significant attention to the vaccine industry to play a representative role.
  • In addition, it is a closed market with a solid local vaccine industry, access to which is challenging for Western players.
  • Meningococcal Meningitis, Pneumococcal, and DTP Vaccine market are expected to control a significant portion of China's vaccine market.
  • The major players covered in the report are Sinopharm Group, Hualan Biological Engineering Inc, Chongqing Zhifei Biological Products Co Ltd, Walvax Biotechnology Co Ltd, Beijing Tiantan Biological Products Corp Ltd, Sinovac Biotech, and Shenzhen Kangtai Biological Products Co Ltd.

Blue Water Vaccines Reports Third Quarter 2022 Financial Results and Recent Business Highlights; Announces 5 Million Share Repurchase Program

Retrieved on: 
Giovedì, Novembre 10, 2022
GLOBE, AOM, S&P, Moraxella catarrhalis, Income, Vaccine, Accounting, Research, Pneumonia, Inactivated vaccine, Travel, Mouse, PCV13, Board, Streptococcus pneumoniae, G&A, Monkeypox, Share repurchase, Haemophilus influenzae, Antibody, CA, Development, Infection, Gastroenteritis, Time, Company, BWV, Disease, Water, Conference, Norovirus, VUK, Private law, Administration, Rotavirus, Cincinnati Children's Hospital Medical Center, Antigen, Congress, Pharmaceutical industry, Insurance, Haemophilus, Jude the Apostle, Streptococcus

On August 11, 2022, BWV closed a private placement with aggregate net cash proceeds of approximately $8.7 million.

Key Points: 
  • On August 11, 2022, BWV closed a private placement with aggregate net cash proceeds of approximately $8.7 million.
  • On November 8, 2022, the Company announced the appointment of Vuk Jeremi to its Board on November 4, 2022.
  • On November 9, 2022, the Board approved a share repurchase program to allow for the Company to repurchase up to 5 million shares, with discretion to management to make purchases subject to market conditions.
  • Cash Position: Cash was $29.1 million as of September 30, 2022, as compared to $1.9 million as of December 31, 2021.

New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical Evaluation

Retrieved on: 
Giovedì, Novembre 10, 2022
Health, Consumer, Infectious Diseases, Children, Clinical Trials, Pharmaceutical, Biotechnology, PCV, PATH, Adult, GBS, Doctor of Philosophy, Severe acute respiratory syndrome coronavirus 2, Immunization, Pneumonia, Center, Technology, Streptococcus, Bill & Melinda Gates Foundation, Sepsis, Peterborough, Safety, Infection, Infant, HIA, Bill, CEO, Death, Volunteering, Meningitis, IVT, Trial of the century, Vaccine, Haemophilus

Biotechnology company Inventprise today announced that a Phase 1/2 clinical study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) has begun in Halifax, Canada.

Key Points: 
  • Biotechnology company Inventprise today announced that a Phase 1/2 clinical study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) has begun in Halifax, Canada.
  • This first-in-human study is an important step in the efforts to develop an affordable, expanded-coverage pneumococcal conjugate vaccine (PCV).
  • Were thrilled to now initiate the proof-of-concept evaluation in the clinic, says Dr. Subhash Kapre, Executive Chairman, Inventprise.
  • Inventprise is a biopharmaceutical company leveraging its innovative platform technology to develop vaccines against infectious diseases with an initial focus on invasive pneumococcal disease.

Global Infectious Diseases Partnering Deal Trends, Players and Financials Analysis Report 2015-2022 - ResearchAndMarkets.com

Retrieved on: 
Martedì, Ottobre 25, 2022
Health, Infectious Diseases, Campylobacter jejuni, MRSA, SEC, Directory, Review, Yellow fever, Salmonella, Global Infectious Disease Epidemiology Network, Chapter Three, Chapter One, Respiratory syncytial virus, Orientation, Contract, RSV, Chapter Five, Research, Anthrax, FIV, Methicillin-resistant Staphylococcus aureus, Escherichia coli, Technology, Haemophilus influenzae, Common cold, HIV, Chapter Six, Foot, Chapter Two, Herpes simplex, Dengue fever, A-Z, Tetanus, Mycobacterium avium complex, Streptococcus, Clostridium difficile, Hepatitis A, Lyme disease, Chapter Four, Pseudomonas aeruginosa, African trypanosomiasis, Hyperlink, Helicobacter pylori, TB, Vaccine, Pharmaceutical industry, Haemophilus, West Nile virus, Infection, Tuberculosis, H1N1, Zika fever, Sepsis, Cytomegalovirus, Diphtheria, Malaria

The "Global Infectious Diseases Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infectious Diseases Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Infectious Diseases Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 2,900 infectious diseases deals.
  • The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.
  • Chapter 6 provides a comprehensive directory of all Infectious Diseases partnering deals by specific Infectious Diseases target announced since 2015.

Global Central Nervous System Partnering Deals Directory 2022: Trends, Players and Financials for 1,700+ Deals Signed Since 2015 - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Agosto 18, 2022
Health, Other Health, Parkinson's disease, Restless legs syndrome, Disease, CNS, Directory, Technology, Dizziness, SEC, Finance, Chapter Four, Multiple sclerosis, Chapter Five, Central nervous system, Chapter Three, Haemophilus influenzae, Restless, Guillain–Barré syndrome, Review, Stroke, Contract, Traumatic brain injury, Amyotrophy, Players, Bacteria, Peripheral neuropathy, Weakness, Chapter Six, Cerebral palsy, Chapter One, Chapter Two, Vertigo, Hyperlink, Migraine, Peripheral nervous system, Spinal cord, Creutzfeldt–Jakob disease, Headache, Mycobacterium tuberculosis, Sclerosis (medicine), TB, A-Z, Pharmaceutical industry, Bank, Risk management, Petroleum, Nausea, Stuttering, Fibromyalgia, Meningitis, Epilepsy, Paralysis, Neuralgia, Pain, Haemophilus

The Global Central Nervous System Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 1,700 central nervous system deals.

Key Points: 
  • The Global Central Nervous System Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 1,700 central nervous system deals.
  • The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.
  • Chapter 6 provides a comprehensive directory of all Central Nervous System partnering deals by specific Central Nervous System target announced since 2015.
  • Global Central Nervous System Partnering 2015 to 2022 includes:
    In Global Central Nervous System Partnering 2015 to 2022, available deals and contracts are listed by:

Global Vaccine Market Analysis Report 2022-2027: Size, Forecasts, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Maggio 26, 2022
Health, Pharmaceutical, CSL Limited, Mumps, Infection, Pediatrics, Ebola, Measles, Prevalence, DPT, Janssen Pharmaceuticals, Chickenpox, Tetanus, COVID-19, Vaccination, Research, Immunization, Man, Diphtheria, Travel, HPV, Health, Death, DPT vaccine, Vaccine, Coronavirus, US, World Bank, Diagnosis, Cervical cancer, Awareness, Haemophilus influenzae, WHO, MMR, BCG, DTP, Meningitis, Ageing, Merck & Co., Inactivated vaccine, Patient, Bill & Melinda Gates Foundation, Industry, Insight, Sanofi Pasteur, Invention, GlaxoSmithKline, Hepatitis, Genetically modified bacteria, Pfizer, UNICEF, Pharmaceutical industry, Growth, Adult, Pneumonia, Haemophilus, Shingles, Rotavirus, Rubella

The "Global Vaccine Market, Size, Global Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Vaccine Market, Size, Global Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Global Vaccines Market is anticipated to reach US$ 86.2 Billion by the year 2027 from $52.5 Billion in 2021.
  • The increasing consumer awareness of adequate immunization for killing various infections catalyzes vaccine market development.
  • Segmentation of Global Vaccines Market:
    In terms of end-user, the vaccine market is divided into pediatrics and adults.

Blue Water Vaccines Reports First Quarter 2022 Financial Results and Recent Business Developments

Retrieved on: 
Venerdì, Maggio 13, 2022
Milton Sapirstein, Microbiology, American Academy, Company, Research, Gastroenteritis, University, Infection, Vaccine, Influenza, Norovirus, Rotavirus, AOM, Technology strategy, American Academy of Pediatrics, Technology, Water, Virology, BWV, S&P, University of Oxford, IPO, Epitope, Streptococcus pneumoniae, Cincinnati Children's Hospital Medical Center, Coronavirus Scientific Advisory Board (Turkey), LLC, Pediatrics, Haemophilus, Nano Research, GLOBE, Security (finance), Online gambling, Pharmaceutical industry, Cryptocurrency, H3N2, Streptococcus

Blue Water Vaccines is a pre-clinical stage biotechnology company developing vaccines against multiple infectious diseases, including influenza, norovirus, rotavirus, and acute otitis media (AOM) from Streptococcus pneumoniae colonization.

Key Points: 
  • Blue Water Vaccines is a pre-clinical stage biotechnology company developing vaccines against multiple infectious diseases, including influenza, norovirus, rotavirus, and acute otitis media (AOM) from Streptococcus pneumoniae colonization.
  • The first quarter of this year had several exciting updates for Blue Water Vaccines, most notably the successful closing of our initial public offering, said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines.
  • We continue to advance our transformational vaccine pipeline to address significant global public health challenges and look forward to sharing additional developments throughout the rest of 2022.
  • In February 2022, the Company appointed James Sapirstein, R.Ph., M.B.A. to the Blue Water Vaccines Board of Directors.

Physicians for Informed Consent Opposes COVID-19 Vaccine Mandate for School Attendance and Doctor Censorship Bills in California

Retrieved on: 
Martedì, Marzo 15, 2022
Decision-making, K-12, Mumps, Informed consent, First, Vaccine, School, Hepatitis B, Statistics, Rubella, Public health, Risk, COVID-19, Science, Senate, Tetanus, Measles, Assembly, Immunodeficiency, Child, Physician, SB, Whooping cough, Chickenpox, Diphtheria, PIC, District of Columbia Voting Rights Amendment, COVID-19 vaccine, Haemophilus influenzae, Pharmaceutical industry, Haemophilus

NEWPORT BEACH, Calif., March 15, 2022 /PRNewswire-PRWeb/ -- Physicians for Informed Consent ( PIC ), an educational nonprofit organization focused on science and statistics, has submitted opposition letters to California Senate Bill 871 (SB 871) and Assembly Bill 2098 (AB 2098).

Key Points: 
  • NEWPORT BEACH, Calif., March 15, 2022 /PRNewswire-PRWeb/ -- Physicians for Informed Consent ( PIC ), an educational nonprofit organization focused on science and statistics, has submitted opposition letters to California Senate Bill 871 (SB 871) and Assembly Bill 2098 (AB 2098).
  • SB 871 proposes a COVID-19 vaccine mandate (without any religious or personal belief exemption) for daycare and K-12 public and private school attendance in California.
  • SB 714 effectively censored physicians in California from expressing their professional medical opinion, through the act of writing letters to schools, that a child's risk of one or more mandated vaccines for school attendance is more than the benefit.
  • Read the Physicians for Informed Consent letters and discuss them with your legislators:

Global Infectious Diseases Partnering Analysis Report 2014-2021: Deal Trends, Players and Financials for Over 2,600 Deals - ResearchAndMarkets.com

Retrieved on: 
Martedì, Gennaio 11, 2022
Health, Infectious Diseases, Helicobacter pylori, Anthrax, Research, Technology, Herpes simplex, Mycobacterium avium complex, Tetanus, TB, Center for Global Infectious Disease Research, Dengue fever, Respiratory syncytial virus, RSV, Campylobacter jejuni, Streptococcus, Escherichia coli, Haemophilus influenzae, MRSA, Hepatitis A, Methicillin-resistant Staphylococcus aureus, Yellow fever, Infection, HIV, Salmonella, Clostridium difficile, FIV, Common cold, Contract, African trypanosomiasis, Foot, Hyperlink, Pseudomonas aeruginosa, A-Z, Lyme disease, Vaccine, Pharmaceutical industry, Aquaculture, Malaria, Diphtheria, West Nile virus, Cytomegalovirus, Sepsis, Tuberculosis, H1N1, Haemophilus, Zika fever

The "Global Infectious Diseases Partnering 2014-2021: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Infectious Diseases Partnering 2014-2021: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.
  • The Global Infectious Diseases Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 2,600 infectious diseases deals.
  • The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.
  • In addition, a comprehensive appendix is provided with each report of all Infectious Diseases partnering deals signed and announced since 2014.